# Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

> **NCT02486484** · PHASE2 · UNKNOWN · sponsor: **Rafic Hariri University Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Neovascularization
- Macular Degeneration
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Choroidal Neovascularization
- Retinal Neovascularization
- Recurrent Pterygium
- Cystoid Macular Edema

## Interventions

- **DRUG:** ziv-aflibercept

## Key facts

- **NCT ID:** NCT02486484
- **Lead sponsor:** Rafic Hariri University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2019-05
- **Final completion:** 2019-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02486484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02486484, "Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02486484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*